Kristina Burow - Apr 2, 2024 Form 4 Insider Report for Boundless Bio, Inc. (BOLD)

Signature
/s/ Jessica Oien, Attorney-in-Fact for Kristina Burow
Stock symbol
BOLD
Transactions as of
Apr 2, 2024
Transactions value $
$3,200,000
Form type
4
Date filed
4/4/2024, 04:30 PM
Previous filing
Mar 27, 2024
Next filing
Jun 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BOLD Common Stock Conversion of derivative security +590K +2156.36% 617K Apr 2, 2024 See footnotes F1, F2, F4, F5
transaction BOLD Common Stock Conversion of derivative security +788K +1919.67% 829K Apr 2, 2024 See footnotes F1, F3, F4, F5
transaction BOLD Common Stock Conversion of derivative security +1.05M 1.05M Apr 2, 2024 See footnotes F1, F6, F7, F8
transaction BOLD Common Stock Purchase $1.07M +66.7K +10.8% $16.00* 684K Apr 2, 2024 See footnotes F2, F4, F5, F9
transaction BOLD Common Stock Purchase $2.13M +133K +12.72% $16.00* 1.18M Apr 2, 2024 See footnotes F6, F7, F8, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -425K -100% 0 Apr 2, 2024 Common Stock 425K See footnotes F1, F2, F4, F5
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -586K -100% 0 Apr 2, 2024 Common Stock 586K See footnotes F1, F3, F4, F5
transaction BOLD Series A Convertible Preferred Stock Conversion of derivative security -454K -100% 0 Apr 2, 2024 Common Stock 454K See footnotes F1, F6, F7, F8
transaction BOLD Series B Convertible Preferred Stock Conversion of derivative security -228K -100% 0 Apr 2, 2024 Common Stock 228K See footnotes F1, F6, F7, F8
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -165K -100% 0 Apr 2, 2024 Common Stock 165K See footnotes F1, F2, F4, F5
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -201K -100% 0 Apr 2, 2024 Common Stock 201K See footnotes F1, F3, F4, F5
transaction BOLD Series C Convertible Preferred Stock Conversion of derivative security -366K -100% 0 Apr 2, 2024 Common Stock 366K See footnotes F1, F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
F2 These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
F3 These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
F4 ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC ("AVP IX MDs"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F5 The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein.
F6 These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
F7 ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any.
F8 The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose.
F9 Reflects shares purchased by ARCH IX in the Issuer's initial public offering.
F10 Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering.